Inclusion Criteria:  Age ≥ 18 years old at time of signing Informed Consent Form Histologically documented diagnosis of locally advanced or metastatic lung cancer (NSCLC or SCLC), surgically resected or advanced melanoma Patients eligible for immunotherapy in any line of treatment, either alone or in combination with other immunotherapy drugs or with chemotherapy Signed Informed Consent Form Life expectancy ≥3 months ECOG Performance Status of ≤2 Adequate hematologic and end-organ function, defined by laboratory test result by investigator's judgment  Viral hepatitis screening:  Negative hepatitis B surface antigen (HBsAg) test For patients with positive total HBcAb test, hepatitis B virus (HBV) DNA test is required For patients with positive HCV antibody test, hepatitis C virus (HCV) RNA test is required  Exclusion Criteria:  Patients receiving immunotherapy at time of enrollment > 1 grade adverse events from previous treatments Any uncontrolled symptom Clinically unstable brain metastases (i.e., symptomatic, not treated with RT and rapidly evolving)